GSK plc (GSK.L)
A global biopharma leader specializing in vaccines and specialty medicines to address complex infectious diseases, HIV, and immune-mediated conditions.
What GSK plc does
GSK is a global biopharma company focused on uniting science, technology, and talent to get ahead of disease. The company researches, develops, and manufactures vaccines and specialty medicines, with a focus on infectious diseases, HIV, respiratory immunology, and oncology.
Themes: vaccines / immunology, HIV treatment, respiratory diseases, oncology drug development, specialty medicines
Fundamentals
- Price£19.10 as of 2026-08-03 close
- Market capn/a company fundamentals are not available for UK-listed companies in our data
- 1-year return+36.7% 2025-08-01 close £13.97 → 2026-08-03 close £19.10
- P/En/a company fundamentals are not available for UK-listed companies in our data
- Net marginn/a company fundamentals are not available for UK-listed companies in our data
- Gross marginn/a company fundamentals are not available for UK-listed companies in our data
- ROEn/a company fundamentals are not available for UK-listed companies in our data
- Debt / equityn/a company fundamentals are not available for UK-listed companies in our data
- Revenue growth (YoY)n/a company fundamentals are not available for UK-listed companies in our data
- Revenue CAGR (3y)n/a company fundamentals are not available for UK-listed companies in our data
- Betan/a we do not track a market benchmark for UK-listed companies
Dividend: company fundamentals are not available for UK-listed companies in our data.
How GSK plc looks technically
GSK plc (GSK.L) is trading 1.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 214 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 10, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 45, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 5 trading days ago (its momentum flipped positive). It made a new 20-day high about 5 trading days ago. It is 16.3% below its highest point of the past year. Trading volume is unusually light — only about 0% of its 30-day average.
Trend
| Distance from the 200-day | +1.9% | it is trading 1.9% above its 200-day average, the long-term trend line — a longer-term uptrend |
|---|---|---|
| 50-day moving average | £19.34 | its average price over the last 50 trading days — a short-term trend line — is £19.34 |
| 200-day moving average | £18.75 | its average price over the last 200 trading days — the long-term trend line — is £18.75 |
| Since the 50/200 cross | 214 sessions | its 50-day average crossed above its 200-day average about 214 trading days ago — a "golden cross", a bullish long-term signal |
| Trend strength (14-day ADX) | 9.5 | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 10, below the 25 that marks a real trend) |
Momentum
| 14-day RSI | 45.0 | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 45, neither overbought (above 70) nor oversold (below 30) |
|---|---|---|
| Since the MACD crossed zero | 5 sessions | MACD, a trend-momentum gauge, turned bullish about 5 trading days ago (its momentum flipped positive) |
Range
| 52-week high | £22.82 | its highest closing price over the past year (about 252 trading days) was £22.82 |
|---|---|---|
| From the 52-week high | -16.3% | it is 16.3% below its 52-week high (its highest price of the past year) |
| Above the 52-week low | +48.2% | it is 48.2% above its 52-week low (its lowest price of the past year) |
| Below the 52-week high | 16.3% | it is 16.3% below its highest point of the past year |
| Since a 20-day breakout | 5 sessions | it made a new 20-day high about 5 trading days ago |
| Since a 55-day breakout | 44 sessions | it made a new 55-day low about 44 trading days ago |
| All-time high | £27.47 | its highest closing price on record is £27.47 (set on 2022-06-14) |
| From the all-time high | -30.5% | it is 30.5% below its all-time high |
| All-time low | £10.96 | its lowest closing price on record is £10.96 (set on 2010-07-06) |
| Above the all-time low | +74.2% | it is 74.2% above its all-time low |
Volatility
| Band width vs its own 6 months | 36th percentile | day-to-day price swings are about average versus its own recent 6-month history |
|---|---|---|
| Bollinger bands (20-day, ±2σ) | £18.65 – £19.43 – £20.20 | most of its recent trading has stayed between about £18.65 and £20.20 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles |
Volume
| Volume vs its 30-day average | 0.00× | trading volume is unusually light — only about 0% of its 30-day average |
|---|
Screens: Near 200-day moving-average support · Trading above the 200-day moving average · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-03. Describes past price behavior only — informational, not financial advice.
Key risks (from latest filing)
["High failure rates in drug and vaccine clinical development programs","Complex regulatory and intellectual property litigation environment","Intense pricing pressure and access constraints from government payers"]
Competitors & peers
- Pfizer (PFE)
- Merck & Co. (MRK)
- Sanofi (SNY)
- Novartis (NVS)
- AstraZeneca (AZN)
- Johnson & Johnson (JNJ)
- Gilead Sciences (GILD)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare GSK.L vs…
Frequently asked questions
What does GSK plc (GSK.L) do?
GSK is a global biopharma company focused on uniting science, technology, and talent to get ahead of disease. The company researches, develops, and manufactures vaccines and specialty medicines, with a focus on infectious diseases, HIV, respiratory immunology, and oncology.
Who are GSK plc's (GSK.L) competitors?
Notable peers of GSK plc (GSK.L) include Pfizer, Merck & Co., Sanofi, Novartis and AstraZeneca. This peer set is informational only — not financial advice.
Is GSK plc (GSK.L) overbought or oversold right now?
GSK plc (GSK.L) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 45, in the neutral middle (as of 2026-08-03). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on GSK.L come from?
Fundamentals and prices come from market data. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data. Prices are delayed daily-close data.
Last updated 2026-08-03.
Informational only — NOT financial advice. All figures are delayed daily-close data from market data, shown with their as-of date.